0
0.5
1
1.5
2+
Mortality
67%
Improvement
Relative Risk
Escalation of care
61%
Escalation of care with po..
34%
Deterioration by >= 2 point..
43%
primary
Fever post randomization
25%
Unresolved symptoms at..
15%
Lack of resolution of symp..
7%
post-hoc primary
Median time to resolution..
17%
no CI
Ivermectin López-Medina et al. EARLY TREATMENT DB RCT
Is early treatment with ivermectin beneficial for COVID-19?
Double-blind RCT 398 patients in Colombia (July - November 2020)
Lower mortality (p=0.5) and progression (p=0.11), not sig.
c19ivm.org
López-Medina et al., JAMA, March 2021
Favors ivermectin
Favors control